We’re proudly independent, free to read, and run by scientists who truly understand Huntington’s disease. That independence means everything, but it also means we rely on support from our community to keep going.
Help us keep the lights on. Every share and donation makes a difference.
A new study puts “self-switching” genetic scissors to work at the root of Huntington’s disease. In mice, this approach was able to step in after symptoms had already begun, offering a glimpse at what future treatments might look like.
en.hdbuzz.net/cutting-to-t...
AI is reshaping Huntington’s disease research, from predicting when symptoms may begin to tracking subtle movement changes through smartwatches.
Here’s where things stand, and why HD is strong candidate for these approaches.
Full Article: en.hdbuzz.net/artificial-i...
New research in an HD mouse model points to a key culprit: HTT1a
Lowering this small fragment delayed disease signs in mice, pointing toward a new direction for next-gen HTT-lowering therapies.
Even in early days, it's a promising step forward.
Full Article: en.hdbuzz.net/blocking-a-t...
A small study based in Ireland asked a simple question: what does caring for someone with Huntington’s disease feel like? The answers point to isolation, stigma, and major gaps in healthcare support for many of the respondents.
Full Article:
en.hdbuzz.net/between-care...
A wrist-worn sensor tracked arm movements over a week and could distinguish between people with HD and those without. Tools like this could transform how we measure the real impact of treatments in clinical trials.
Full Article: en.hdbuzz.net/your-wrist-o...
March brought us the annual CHDI therapeutics conference along with updates from 3 ongoing clinical trials. We also covered new research on somatic expansion and honored the community that built our science during Gratitude Day.
en.hdbuzz.net/march-2026-t...
A new study suggests simple rhythmic cues beat complex music or instructions in music + physical therapy, improving movement control and reducing chorea.
en.hdbuzz.net/two-heads-ar...
Today, on Gratitude Day, we share a guest piece from HD researcher Roy Maimon that Huntington’s disease is neuroscience’s best investment, not just for its scientific clarity, but for the remarkable community built around it.
Full Article: en.hdbuzz.net/a-guest-pers...
Join the Factor-H livestream from Venezuela:
🗓 March 22, 2026
⏰ 9AM PST | 12PM EST | 5PM UK | 6PM EU
🔗 us06web.zoom.us/meeting/register/_3zDACtIQfekFZblQC8PWA
Share your support with #HDGratitudeDay
Gratitude Day is for the whole HD community. Families, scientists, clinicians, and caregiver, every advance in HD has come from this partnership. We’re all in this together.
This Gratitude Day, we honour the powerful partnership between HD families, scientists, and caregivers, and reflect on the place that built the foundation of the science we stand on today.
Full Article: en.hdbuzz.net/the-girl-at-...
Novartis has confirmed that the first clinical sites for INVEST-HD, the Phase 3 trial of votoplam, are now open. The study plans to recruit around 770 participants across 30+ countries, marking a major step forward in advancing potential treatments for Huntington’s disease.
Scientists reduced CAG repeat expansion by up to 69% in a human cellular system by dialing back mismatch repair genes. It’s early research, but it points to the potential of “anti-expansion” therapies that could help delay Huntington’s disease onset.
Full Article: en.hdbuzz.net/turning-down...
Day 3 of the HD Therapeutics Conference is bringing even more breakthrough science, new tools, and bold ideas pushing Huntington’s disease research closer to better treatments. Read today's article for the latest updates from the conference.
Full Article: en.hdbuzz.net/huntingtons-...
These sessions highlighted techniques that allow scientists to zoom in on Huntington’s disease biology in extraordinary detail, helping researchers better understand what’s happening inside cells and how it might be targeted with future treatments.
en.hdbuzz.net/huntingtons-...
HDBuzz is back with Day 2 of the 21st annual CHDI HD Therapeutics Conference in Palm Springs.
HDBuzz was at the HD Therapeutics Conference, and brought you live updates on the latest research in Huntington’s disease.
Read up on the exciting science, new discoveries, and insights straight from the researchers working to move the field forward.
en.hdbuzz.net/huntingtons-...
From scientists in the lab to the research participants driving discoveries forward, we recognize the women shaping the future of science and medicine.
This International Women’s Day, we celebrate the dedication, courage, and brilliance of all the women moving research forward every single day.
An oral Huntington’s disease drug has been deemed eligible for accelerated approval in Australia. While this isn’t full approval just yet, it creates a faster regulatory pathway that could help bring this once-daily pill to people living with HD sooner.
en.hdbuzz.net/australia-op...
The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required en.hdbuzz.net/the-road-ahe...
Vico Therapeutics’ Huntington’s disease drug VO659 is now being tested with dosing just twice a year, and the FDA has cleared the path for US clinical trials to begin later this year.
Full article: en.hdbuzz.net/vicos-trial-...
On Rare Disease Day, we honour the patients, caregivers, clinicians, and researchers who push for answers, better treatments, and equity in care. Awareness sparks research. Research sparks hope.
Today we stand with the millions of individuals and families around the world living with a rare disease. Though each condition may be uncommon, together this community is powerful, resilient, and impossible to ignore.
And that wraps the #HDTC2026 meeting! As always, we’re floored by the novelty and diversity of ideas moving us closer to treatments for HD. Summary articles will follow, so stay tuned!
Claudia has applied a bottom-up approach to connect very rare symptomatic observations with new genetic causes. She is also applying meta-analyses that combine findings from multiple studies for an even richer collection of “big data.” #HDTC2026
To overcome this challenge, there are ongoing efforts to diversify these databases with participation from folks who come from all over the world. Hopefully this means that moving forward, gene-health connection research can be more inclusive. #HDTC2026
This kind of analysis is only made possible because of the tens of thousands of folks who participate in data collection efforts. However, these databases are dominated by people of European ancestry, which means these trends might not hold true for people from other backgrounds. #HDTC2026